Investing.com - Legend Bio reported on Friday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Legend Bio announced earnings per share of $-0.2959 on revenue of $36.37M. Analysts polled by Investing.com EPS of $-0.3102 on revenue of $33.62M.
Legend Bio 's are down 1% and is trading at $46.13 , still down 20.47% from its 52 week high of $58.00 set on Tuesday, October 12, 2021.
Legend Bio follows other major Healthcare sector earnings this month
Legend Bio's report follows an earnings beat by Medtronic on Tuesday, August 23, 2022, who reported EPS of $1.13 on revenue of $7.37B, EPS of $1.12 on revenue of $7.22B.
Agilent Technologies had beat expectations on Tuesday, August 16, 2022 with third quarter EPS of $1.34 on revenue of $1.72B, for EPS of $1.2 on revenue of $1.64B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar